Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS
August 4, 2015 4:10 PM EDT
Multiple potential milestones in 2H 2015
Conference call scheduled for 4:30 p.m. EDT today
FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the second quarter ended June 30, 2015.
"During the second quarter of 2015, we initiated a Phase 1 study of VTP-43742, our first-in-class RORt candidate for the treatment of autoimmune disorders. Initiation of this study was a... More
August 4, 2015 4:10 PM EDT
Multiple potential milestones in 2H 2015
Conference call scheduled for 4:30 p.m. EDT today
FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the second quarter ended June 30, 2015.
"During the second quarter of 2015, we initiated a Phase 1 study of VTP-43742, our first-in-class RORt candidate for the treatment of autoimmune disorders. Initiation of this study was a... More
